An Oxford business which specialises in technologies for drug and gene therapy development has secured £6.5m as part of a syndicated funding round.

The cash injection values Oxford Genetics, which is based at Oxford Science Park, at £30.5m.

The funding was provided by Canaccord Genuity, Invesco Asset Management and Mercia.

Ryan Cawood, founder and chief executive of Oxford Genetics, said: “This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.

For further information and to read the full article, please click here

GET IN TOUCH!


  MAIL US
enquiries@growthinvest.com

  CALL US
020 7071 3945

FOLLOW US ON


Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.